firategrast
Small moleculeexperimental
Clinical trial activity
8 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2004 (NCT00097331)
Timeline
Indications
Mechanism of action
- Integrin alpha-4/beta-7ANTAGONIST
Integrin alpha-4/beta-7 antagonist
- Integrin alpha-4/beta-1ANTAGONIST
Integrin alpha-4/beta-1 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CCOCc1cc(OC)c(-c2ccc(C[C@H](NC(=O)c3c(F)cccc3F)C(=O)O)cc2)c(OC)c1- Mol. weight
- 499.51 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2104967 ↗
Also known as
- 683699
- firategrast
- firategrast
- firategrast
- firategrast
- firategrast
- sb683699
- sb683699
- sb683699
- sb-683699
- sb-683699
- sb-683699
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02832765 | Phase 2 | Sep 1, 2016 | University of Heidelberg |
| NCT01416363 | Phase 1 | May 1, 2011 | GlaxoSmithKline |
| NCT01424462 | Phase 1 | Apr 19, 2010 | GlaxoSmithKline |
| NCT00469378 | Phase 2 | Jul 1, 2007 | GlaxoSmithKline |
| NCT00548769 | Phase 1 | Apr 1, 2007 | GlaxoSmithKline |
| NCT00395317 | Phase 2 | Dec 1, 2006 | GlaxoSmithKline |
| NCT00101946 | Phase 2 | Oct 1, 2004 | GlaxoSmithKline |
| NCT00097331 | Phase 2 | Sep 1, 2004 | GlaxoSmithKline |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 7 | 7 | 2 | 2004 |
| University of Heidelberg | Academic/Hospital | 1 | 1 | 1 | 2016 |
2 organizations
Page 1 / 1